LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Vitamin D Levels Tied to COVID-19 Risk for African-Americans

By LabMedica International staff writers
Posted on 29 Mar 2021
Print article
Image: A blood test for Vitamin D showed that African-Americans individuals with low Vitamin D were more at risk from COVID-19 (Photo courtesy of Getty Images)
Image: A blood test for Vitamin D showed that African-Americans individuals with low Vitamin D were more at risk from COVID-19 (Photo courtesy of Getty Images)
Vitamin D has diverse physiological effects, including on calcium regulation, bone density, and immune function. Deficient levels, typically defined as 25-hydroxyvitamin D (also known as calcifediol) level less than 20 ng/mL are common, especially in African-Americans individuals.

Vitamin D is also important for immune function, and a meta-analysis of randomized clinical trials using daily or weekly dosing has found vitamin D supplementation was associated with substantially decreased viral respiratory infections, especially in individuals who were deficient in vitamin D, but also individuals without a deficient level.

A team of Medical Scientists from The University of Chicago (Chicago, IL, USA) examined whether COVID-19 test results are associated with differences in vitamin D levels of 30 ng/mL or greater, including for White individuals and for African-Americans individuals. The team assessed data from 4,638 people tested for COVID-19 from March 3, 2020 to April 10, 2020, who also had data on vitamin D levels within a year prior to COVID-19 testing. COVID-19 status was determined by the Centers for Disease Control and Prevention or Viacor polymerase chain reaction (PCR, Lee's Summit, MO, USA) test used until in-house testing with the Cobas SARS-CoV-2 RT-PCR (Roche Diagnostics, Rotkreuz, Switzerland) began March 15, 2020.

The primary outcome was whether vitamin D level within 14 days was associated with testing positive for COVID-19, and the group controlled for time and vitamin D treatment changes since the vitamin D level was measured, as well as demographic characteristics and comorbidity indicators. The team reported that patients' mean age was around 53 and 69% were women; 49% were African-Americans and 43% were White. They were stratified into four groups by vitamin D levels. African-Americans individuals were more likely than White individuals to have vitamin D levels below 20 ng/mL (36% and 16%, respectively), and more likely to test positive for COVID-19 (9% and 5%, respectively). COVID-19 risk decreased by 5% for each 1 ng/mL increment among individuals with a level of 30 ng/mL or greater in African-Americans individuals.

The authors concluded that COVID-19 risk increased among African-Americans individuals with vitamin D level less than 40 ng/mL compared with those with 40 ng/mL or greater and decreased with increasing levels among individuals with levels greater than 30 ng/mL. No significant associations were noted for White individuals. The study was published on March 19, 2021 in the journal JAMA Network Open.

Related Links:
The University of Chicago
Viacor
Roche Diagnostics


Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.